How should IGF-1 LR3 be stored and reconstituted?

Lyophilised IGF-1 LR3 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What should I look for in IGF-1 LR3 sourcing and quality?

Acceptable IGF-1 LR3 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 9111 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How do I schedule IGF-1 LR3 alongside my existing stack?

IGF-1 LR3's schedule is built around its ~20-30 hr (vs ~10 min for native IGF-1) pharmacokinetics and 1-2x daily subq dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

What is the standard dosing protocol for IGF-1 LR3?

Conventional IGF-1 LR3 dosing is 20-50 mcg 1-2x daily subq via subq. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How long until I see results from IGF-1 LR3?

Acute effects from IGF-1 LR3 appear within hours of dosing for receptor-level changes. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Home/ Compounds/ IGF-1 LR3

IGF-1 LR3

Protocol

Protocol design for IGF-1 LR3 starts with pharmacokinetics and ends with calendar planning. The compound's ~20-30 hr (vs ~10 min for native IGF-1) half-life via subq administration places it in the multi-daily-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.

Protocol / Scheduling / Cycling Applications

Tapered CyclesOff-TimeWash-OutStorage During CycleMaintenance Phase

Key Takeaways

Scheduling lens: IGF-1 LR3's ~20-30 hr (vs ~10 min for native IGF-1) half-life via subq places it in the multi-daily-dosing bucket.
Mechanism: Binds the IGF-1 receptor with full agonist activity.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for IGF-1 LR3.

Cycle length and off-cycle planning

Standard IGF-1 LR3 cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Stack scheduling with other compounds

When IGF-1 LR3 is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any IGF-1 LR3 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most IGF-1 LR3 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Protocol / Scheduling / Cycling Applications

Travel Considerations

The most-asked scheduling question for IGF-1 LR3 in travel considerations is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Loading Phase

Schedule design for IGF-1 LR3 in loading phase starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Protocol Calendar

For protocol calendar scheduling, IGF-1 LR3 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Cycle Design

The most-asked scheduling question for IGF-1 LR3 in cycle design is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	20-50 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	12-50 mcg	4–6 weeks initial cycle
Protocol focus	SubQ	20-50 mcg	1-2x daily SubQ
Maintenance phase	SubQ	14-50 mcg	Ongoing with periodic pauses

Dose timing for IGF-1 LR3 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

IGF-1 LR3 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

IGF-1 LR3 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with IGF-1 LR3's mechanism in protocol / scheduling / cycling protocols.
IGF-1 LR3 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with IGF-1 LR3's mechanism in protocol / scheduling / cycling protocols.
IGF-1 LR3 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with IGF-1 LR3's mechanism in protocol / scheduling / cycling protocols.
IGF-1 LR3 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with IGF-1 LR3's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Unapproved (research reagent) Research: Animal models; off-label use widespread

Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy.

Lens-specific safety considerations for protocol / scheduling / cycling use of IGF-1 LR3: Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Long-R3 IGF-I — properties and uses

PMID 1429592

Supporting

IGF-1 LR3 muscle effects

PMID 10393945

IGF-1 LR3 vs Related Peptides

Compound	Profile	Onset	Best For
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

What does IGF-1 LR3 stack well with?

For protocol / scheduling / cycling protocols, IGF-1 LR3 pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from IGF-1 LR3's primary mechanism (Binds the IGF-1 receptor with full agonist activity), producing additive or synergistic effects rather than receptor competition.

How does IGF-1 LR3's half-life affect dosing?

IGF-1 LR3 has a plasma half-life of ~20-30 hr (vs ~10 min for native IGF-1), which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1-2x daily subq dosing at 20-50 mcg per dose explains the typical onset timeline for scheduling and cycle endpoints.

Clinical Protocol

Start a IGF-1 LR3 Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified IGF-1 LR3 and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 9111 Da
Sequence length: 83 aa
Half-life: ~20-30 hr (vs ~10 min for native IGF-1)
WADA: Banned (S2)
FDA: Unapproved (research reagent)
Research: Animal models; off-label use widespread

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for IGF-1 LR3 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for IGF-1 LR3

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised